Over the years, we have received a lot of questions about cytochrome P450 (CYP) 2C induction studies. In February of 2021, Andrew G. Taylor, Ph.D., Technical Sales Specialist, and Becky Campbell, Principal Scientist in Technical Advising, provided a webinar on utilizing CYP2C induction studies for successful preclinical risk assessment to answer some of the most common questions. This post encompasses the key takeaways from their presentation.